Regeneron Pharmaceuticals(REGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

REGN Regeneron Pharmaceuticals

Post-Mkt 02-24 18:10:27 EST

772.19

-14.85

-1.89%

盘后772.19

+0.000.00%

17:33 EST

High792.67	Low768.75	Vol628.66K
Open780.47	D1 Closing787.04	Amplitude3.04%
Mkt Cap81.64B	Tradable Cap79.77B	Total Shares105.72M
T/O487.52M	T/O Rate0.61%	Tradable Shares103.30M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"REGN","market":"US","secType":"STK","nameCN":"Regeneron Pharmaceuticals","latestPrice":772.19,"timestamp":1771966800000,"preClose":787.04,"halted":0,"volume":628661,"hourTrading":{"tag":"盘后","latestPrice":772.19,"preClose":772.19,"latestTime":"17:33 EST","volume":23384,"amount":18056912.0056,"timestamp":1771972422539,"change":0,"changeRate":0,"amplitude":0.006672},"delay":0,"changeRate":-0.01886816426102855,"floatShares":103302739,"shares":105719806,"eps":41.59414,"marketStatus":"Post-Mkt","change":-14.85,"latestTime":"02-24 18:10:27 EST","open":780.47,"high":792.67,"low":768.75,"amount":487521073.2832,"amplitude":0.030392,"askPrice":788,"askSize":44,"bidPrice":767,"bidSize":5,"shortable":3,"etf":0,"ttmEps":41.59414,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1771981200000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":787.04,"dividendRate":0.004558,"preHourTrading":{"tag":"盘前","latestPrice":781.08,"preClose":787.04,"latestTime":"09:29 EST","volume":343,"amount":269131.10839999997,"timestamp":1771943399999,"change":-5.96,"changeRate":-0.007573,"amplitude":0.011334},"postHourTrading":{"tag":"盘后","latestPrice":772.19,"preClose":772.19,"latestTime":"17:33 EST","volume":23384,"amount":18056912.0056,"timestamp":1771972422539,"change":0,"changeRate":0,"amplitude":0.006672},"volumeRatio":1.029216,"impliedVol":0.3694,"impliedVolPercentile":0.3984},"requestUrl":"/m/hq/s/REGN","defaultTab":"news","newsList":[{"id":"2614725362","title":"Regeneron Pharmaceuticals Inc. Stock Underperforms Tuesday When Compared To Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2614725362","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614725362?lang=en_us&edition=fundamental","pubTime":"2026-02-25 05:42","pubTimestamp":1771969320,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Regeneron Pharmaceuticals Inc.  shed 1.89% to $772.19 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index  rising 0.77% to 6,890.07 and the Dow Jones Industrial Average  rising 0.76% to 49,174.50.Regeneron Pharmaceuticals Inc. closed 5.96% below its 52-week high of $821.11, which the company reached on January 9th.The stock underperformed when compared to some of its competitors Tuesday, as Amgen Inc.  rose 0.91% to $382.87, Moderna Inc.  rose 0.46% to $50.52, and Gilead Sciences Inc.  fell 1.46% to $147.64.Trading volume  remained 221,182 below its 50-day average volume of 849,498.Data source: Dow Jones Market Data, FactSet. Data compiled February 24, 2026.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Jou","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"gpt_icon":0},{"id":"2613710794","title":"Regeneron, Sanofi announce FDA approval of Dupixent for AFRS","url":"https://stock-news.laohu8.com/highlight/detail?id=2613710794","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613710794?lang=en_us&edition=fundamental","pubTime":"2026-02-24 22:35","pubTimestamp":1771943734,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the U.S. Food and Drug Administration has approved Dupixent for the treatment of a...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/regeneron-sanofi-announce-fda-approval-of-dupixent-for-afrs-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/regeneron-sanofi-announce-fda-approval-of-dupixent-for-afrs-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","LU2362541513.USD","LU2468319806.SGD","IE00BFXG1179.USD","LU0823416689.USD","LU2023250504.SGD","LU0114720955.EUR","LU1917777945.USD","REGN","LU2362540622.SGD","LU0058720904.USD","LU0882574055.USD","LU0889565916.HKD","LU2237438978.USD","LU2362541273.HKD","LU0320765992.SGD","LU0289739699.SGD","BK4139","BK4007","LU0823434583.USD","LU0823434740.USD","LU0109394709.USD","LU0053666078.USD","SNY","LU1974910355.USD","BK4588","LU2106854487.HKD","SNYNF","LU2089984988.USD"],"gpt_icon":0},{"id":"2613710989","title":"FDA approves Sanofi and Regeneron’s Dupixent for allergic fungal rhinosinusitis in patients aged 6 and older","url":"https://stock-news.laohu8.com/highlight/detail?id=2613710989","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613710989?lang=en_us&edition=fundamental","pubTime":"2026-02-24 22:30","pubTimestamp":1771943427,"startTime":"0","endTime":"0","summary":"Sanofi SA and Regeneron Pharmaceuticals said the US Food and Drug Administration approved Dupixent  to treat allergic fungal rhinosinusitis in adults and children aged 6 years and older who have a history of sino-nasal surgery. The approval was supported by the phase 3 LIBERTY-AFRS-AIMS study and was reviewed under the FDA’s priority review program.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nNDL8XMZsp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","BK4585","LU2362541513.USD","LU2106854487.HKD","LU2095319765.USD","BK4139","IE00B3QW5Z07.USD","LU2362540622.SGD","LU0053666078.USD","LU1974910355.USD","SG9999014039.USD","LU0109394709.USD","LU0889565916.HKD","BK4112","SG9999014021.USD","SG9999014013.SGD","LU2210150020.SGD","LU1917777945.USD","LU2237438978.USD","LU0823434740.USD","IE00BKPKM429.USD","NDAQ","LU0114720955.EUR","BK4588","LU2023250504.SGD","LU2468319806.SGD","LU0823434583.USD","LU2362541273.HKD","LU0058720904.USD","SG9999014005.SGD","LU2089984988.USD","LU0320765992.SGD","IE00B64PRP62.GBP","LU0823416689.USD","LU0314104364.USD","REGN","LU2210149790.SGD","LU0289739699.SGD","LU0882574055.USD"],"gpt_icon":0},{"id":"2613939710","title":"Sanofi - Phase 3 Study Shows Dupixent Reduces Nasal Signs and Symptoms","url":"https://stock-news.laohu8.com/highlight/detail?id=2613939710","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613939710?lang=en_us&edition=fundamental","pubTime":"2026-02-24 22:30","pubTimestamp":1771943401,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nTUA48NKDX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0114720955.EUR","LU1974910355.USD","LU0320765992.SGD","LU2023250504.SGD","LU0889565916.HKD","LU0823434583.USD","REGN","LU2106854487.HKD","LU2468319806.SGD","LU0053666078.USD","BK4588","LU2362540622.SGD","LU0823434740.USD","LU0058720904.USD","LU2237438978.USD","LU1917777945.USD","LU0289739699.SGD","LU0882574055.USD","LU2362541513.USD","LU2362541273.HKD","LU0823416689.USD","LU0109394709.USD","BK4585","BK4139","LU2089984988.USD"],"gpt_icon":0},{"id":"2613710958","title":"Sanofi - Approval Expands Our Approved Indications in Sino-Nasal Diseases to NOW Include Afrs, Alongside Chronic Rhinosinusitis With Nasal Polyps","url":"https://stock-news.laohu8.com/highlight/detail?id=2613710958","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613710958?lang=en_us&edition=fundamental","pubTime":"2026-02-24 22:30","pubTimestamp":1771943401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nTUA48NKDX:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["REGN","LU0053666078.USD","BK4585","LU0823416689.USD","LU0289739699.SGD","LU2089984988.USD","LU2106854487.HKD","LU2023250504.SGD","LU0058720904.USD","LU0320765992.SGD","LU2362541513.USD","LU0823434583.USD","BK4139","LU0109394709.USD","LU1974910355.USD","LU2362540622.SGD","LU2468319806.SGD","LU0882574055.USD","LU1917777945.USD","LU0823434740.USD","LU0114720955.EUR","LU0889565916.HKD","BK4588","LU2237438978.USD","LU2362541273.HKD"],"gpt_icon":0},{"id":"2613106637","title":"Press Release: Sanofi and Regeneron’s Dupixent Approved in the US as the First and Only Medicine for Allergic Fungal Rhinosinusitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2613106637","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613106637?lang=en_us&edition=fundamental","pubTime":"2026-02-24 22:30","pubTimestamp":1771943401,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nTUA48NKDX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1974910355.USD","LU2362540622.SGD","BK4139","LU2089984988.USD","LU0053666078.USD","LU0882574055.USD","BK4588","LU0114720955.EUR","LU0058720904.USD","LU0823434740.USD","LU2468319806.SGD","LU2023250504.SGD","LU0289739699.SGD","LU2106854487.HKD","LU0823434583.USD","BK4585","LU2362541513.USD","LU0889565916.HKD","LU0823416689.USD","LU2237438978.USD","REGN","LU1917777945.USD","LU2362541273.HKD","LU0320765992.SGD","LU0109394709.USD"],"gpt_icon":0},{"id":"2613758934","title":"Regeneron Director Huda Y. Zoghbi Disposes of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2613758934","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613758934?lang=en_us&edition=fundamental","pubTime":"2026-02-24 05:56","pubTimestamp":1771883801,"startTime":"0","endTime":"0","summary":"Huda Y. Zoghbi, a director of Regeneron Pharmaceuticals Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regeneron Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 23, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nNDL1XgTPC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Regeneron Director Huda Y. Zoghbi Disposes of Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","LU2362541513.USD","LU0823434583.USD","LU0320765992.SGD","LU1974910355.USD","LU0109394709.USD","LU1917777945.USD","LU2362540622.SGD","LU2089984988.USD","LU0823434740.USD","LU0289739699.SGD","LU0053666078.USD","LU2106854487.HKD","LU2237438978.USD","LU2362541273.HKD","BK4585","LU0058720904.USD","BK4139","LU2023250504.SGD","LU2468319806.SGD","LU0114720955.EUR","REGN","LU0823416689.USD","LU0882574055.USD","BK4588"],"gpt_icon":0},{"id":"2612267522","title":"BMO Capital Adjusts Price Target on Regeneron Pharmaceuticals to $900 From $850, Maintains Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2612267522","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612267522?lang=en_us&edition=fundamental","pubTime":"2026-02-20 21:48","pubTimestamp":1771595300,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals (REGN) has an average rating of overweight and mean price target of $877.75, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic resea","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["REGN","BMO"],"gpt_icon":0},{"id":"2612029914","title":"Garetosmab Biologics License Application Accepted For FDA Priority Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2612029914","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612029914?lang=en_us&edition=fundamental","pubTime":"2026-02-19 20:17","pubTimestamp":1771503435,"startTime":"0","endTime":"0","summary":"Feb 19 (Reuters) - Regeneron Pharmaceuticals Inc ::*GARETOSMAB BIOLOGICS LICENSE APPLICATION ACCEPTED FOR FDA PRIORITY REVIEW FOR THE TREATMENT OF FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP)*REGENERON","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nRSD5sC1TK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823434583.USD","BK4588","LU0289739699.SGD","REGN","LU0320765992.SGD","LU0058720904.USD","BK4585","LU0882574055.USD","LU2362541273.HKD","LU2106854487.HKD","LU0889565916.HKD","LU1917777945.USD","LU2023250504.SGD","LU1974910355.USD","LU2468319806.SGD","LU2362540622.SGD","LU0823416689.USD","LU0053666078.USD","LU0114720955.EUR","LU2089984988.USD","LU2237438978.USD","LU0823434740.USD","LU0109394709.USD","LU2362541513.USD","BK4139"],"gpt_icon":0},{"id":"2612404247","title":"FDA accepts Regeneron’s garetosmab BLA for priority review in FOP","url":"https://stock-news.laohu8.com/highlight/detail?id=2612404247","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612404247?lang=en_us&edition=fundamental","pubTime":"2026-02-19 20:01","pubTimestamp":1771502511,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals said the FDA has accepted its Biologics License Application for garetosmab to treat adults with fibrodysplasia ossificans progressiva  and granted the application Priority Review. The FDA’s target action date for a decision is August 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regeneron Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire  on February 19, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nNDLVmf4Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU2210150020.SGD","LU0114720955.EUR","NDAQ","LU2023250504.SGD","SG9999014039.USD","IE00B64PRP62.GBP","LU2237438978.USD","LU1917777945.USD","LU0053666078.USD","LU2362540622.SGD","LU0314104364.USD","BK4588","LU0889565916.HKD","SG9999014021.USD","BK4139","IE00BGHQF748.EUR","LU0320765992.SGD","LU0289739699.SGD","LU2095319765.USD","LU0058720904.USD","LU2362541513.USD","LU2468319806.SGD","LU2106854487.HKD","LU0109394709.USD","LU0823434583.USD","REGN","LU2089984988.USD","SG9999014005.SGD","IE00B3QW5Z07.USD","LU2362541273.HKD","LU0882574055.USD","LU1974910355.USD","BK4585","IE00BKPKM429.USD","LU0823416689.USD","SG9999014013.SGD","LU0823434740.USD","LU2210149790.SGD"],"gpt_icon":0},{"id":"2612840414","title":"Regeneron Pharmaceuticals Inc - FDA Decision Expected by August 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2612840414","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612840414?lang=en_us&edition=fundamental","pubTime":"2026-02-19 20:00","pubTimestamp":1771502401,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nTUA3KNHG5:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1974910355.USD","LU2362540622.SGD","BK4139","LU2089984988.USD","LU0053666078.USD","LU0882574055.USD","BK4588","LU0114720955.EUR","LU0058720904.USD","LU0823434740.USD","LU2468319806.SGD","LU2023250504.SGD","LU0289739699.SGD","LU2106854487.HKD","LU0823434583.USD","BK4585","LU2362541513.USD","LU0889565916.HKD","LU0823416689.USD","LU2237438978.USD","REGN","LU1917777945.USD","LU2362541273.HKD","LU0320765992.SGD","LU0109394709.USD"],"gpt_icon":0},{"id":"2612407826","title":"Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2612407826","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612407826?lang=en_us&edition=fundamental","pubTime":"2026-02-19 20:00","pubTimestamp":1771502400,"startTime":"0","endTime":"0","summary":"FOP is an ultra-rare genetic disorder characterized by abnormal bone formation that infiltrates muscles, tendons, ligaments and other connective tissues, resulting in significant disability If approve","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/19/3240927/0/en/Garetosmab-Biologics-License-Application-Accepted-for-FDA-Priority-Review-for-the-Treatment-of-Fibrodysplasia-Ossificans-Progressiva-FOP.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0114720955.EUR","LU2237438978.USD","LU2362541513.USD","BK4585","LU0823434583.USD","LU0289739699.SGD","LU0109394709.USD","LU0889565916.HKD","LU0053666078.USD","LU2362541273.HKD","LU0823434740.USD","LU2468319806.SGD","LU1917777945.USD","REGN","LU2089984988.USD","LU2362540622.SGD","LU0882574055.USD","LU0320765992.SGD","LU2106854487.HKD","LU0823416689.USD","BK4588","LU0058720904.USD","LU2023250504.SGD","LU1974910355.USD","BK4139"],"gpt_icon":0},{"id":"2612408993","title":"Citi Reaffirms Their Buy Rating on Regeneron (REGN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2612408993","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612408993?lang=en_us&edition=fundamental","pubTime":"2026-02-19 15:56","pubTimestamp":1771487765,"startTime":"0","endTime":"0","summary":"Citi analyst Geoff Meacham maintained a Buy rating on Regeneron yesterday. The company’s shares closed yesterday at $792.16. According to TipRanks,...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/citi-reaffirms-their-buy-rating-on-regeneron-regn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/citi-reaffirms-their-buy-rating-on-regeneron-regn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["REGN"],"gpt_icon":0},{"id":"2612493647","title":"Regeneron Pharmaceuticals Inc. Stock Underperforms Tuesday When Compared To Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2612493647","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612493647?lang=en_us&edition=fundamental","pubTime":"2026-02-18 05:42","pubTimestamp":1771364520,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Regeneron Pharmaceuticals Inc.  slid 1.20% to $793.53 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index  rising 0.10% to 6,843.22 and the Dow Jones Industrial Average  rising 0.07% to 49,533.19.The stock's fall snapped a three-day winning streak.Regeneron Pharmaceuticals Inc. closed 3.36% below its 52-week high of $821.11, which the company reached on January 9th.The stock underperformed when compared to some of its competitors Tuesday, as Amgen Inc.  rose 1.13% to $373.36, Moderna Inc.  rose 4.03% to $43.93, and Gilead Sciences Inc.  rose 0.19% to $155.27.Trading volume  remained 135,816 below its 50-day average volume of 882,711.Data source: Dow Jones Market Data, FactSet. Data compiled February 17, 2026.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"gpt_icon":0},{"id":"2612945487","title":"Canaccord Genuity Reaffirms Their Buy Rating on Regeneron (REGN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2612945487","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612945487?lang=en_us&edition=fundamental","pubTime":"2026-02-17 20:17","pubTimestamp":1771330656,"startTime":"0","endTime":"0","summary":"Canaccord Genuity analyst John Newman maintained a Buy rating on Regeneron today and set a price target of $1,057.00. According to TipRanks, Newman...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-reaffirms-their-buy-rating-on-regeneron-regn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-reaffirms-their-buy-rating-on-regeneron-regn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["REGN"],"gpt_icon":0},{"id":"2612451453","title":"Ocular Therapeutix plunges as modest benefit overshadow trial win over Regeneron's Eylea","url":"https://stock-news.laohu8.com/highlight/detail?id=2612451453","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612451453?lang=en_us&edition=fundamental","pubTime":"2026-02-17 20:08","pubTimestamp":1771330123,"startTime":"0","endTime":"0","summary":"UPDATE 3-Ocular Therapeutix plunges as modest benefit overshadow trial win over Regeneron's EyleaAxpaxli shows modest advantage over Eylea in trialRetinal specialists may value trial data more than in","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nL4N3ZD0QA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053666078.USD","LU0058720904.USD","LU0823434583.USD","LU0889565916.HKD","LU1917777945.USD","LU2362540622.SGD","LU2362541273.HKD","OCUL","LU1974910355.USD","LU0882574055.USD","LU0320765992.SGD","BK4139","LU2362541513.USD","BK4007","LU0823434740.USD","LU2237438978.USD","LU0109394709.USD","LU0114720955.EUR","LU2468319806.SGD","BK4585","LU0823416689.USD","LU2089984988.USD","REGN","BK4588","LU2023250504.SGD","LU2106854487.HKD","LU0289739699.SGD"],"gpt_icon":0},{"id":"2612459035","title":"Ocular Therapeutix's eye drug superior to Regeneron's Eylea in late-stage trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2612459035","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612459035?lang=en_us&edition=fundamental","pubTime":"2026-02-17 20:00","pubTimestamp":1771329600,"startTime":"0","endTime":"0","summary":"Ocular Therapeutix's eye drug superior to Regeneron's Eylea in late-stage trialFeb 17 (Reuters) - Ocular Therapeutix OCUL.O said on Tuesday its experimental eye disease drug was more effective in help","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nL4N3ZC0JU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053666078.USD","REGN","LU2237438978.USD","LU0114720955.EUR","LU0889565916.HKD","LU2362541513.USD","BK4588","LU1974910355.USD","LU0320765992.SGD","LU1917777945.USD","LU0823434583.USD","BK4139","LU2106854487.HKD","LU2023250504.SGD","LU0823416689.USD","LU0823434740.USD","BK4007","LU0289739699.SGD","LU2362540622.SGD","OCUL","LU0058720904.USD","LU2362541273.HKD","LU0882574055.USD","BK4585","LU0109394709.USD","LU2468319806.SGD","LU2089984988.USD"],"gpt_icon":0},{"id":"2611370161","title":"Regeneron Advances REGN7508 Into Phase 3 To Tackle Cancer-Linked Blood Clots","url":"https://stock-news.laohu8.com/highlight/detail?id=2611370161","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611370161?lang=en_us&edition=fundamental","pubTime":"2026-02-14 00:32","pubTimestamp":1771000329,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals ($REGN) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals (REGN) is launching a Phase 3 tria...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/regeneron-advances-regn7508-into-phase-3-to-tackle-cancer-linked-blood-clots?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/regeneron-advances-regn7508-into-phase-3-to-tackle-cancer-linked-blood-clots?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0289739699.SGD","LU0823416689.USD","LU2468319806.SGD","LU0823434583.USD","BK4585","LU2023250504.SGD","LU0114720955.EUR","LU0320765992.SGD","LU2362540622.SGD","BK4139","REGN","LU2362541273.HKD","LU0058720904.USD","BK4588","LU2362541513.USD","LU0109394709.USD","LU0882574055.USD","LU0823434740.USD","LU0053666078.USD","LU0889565916.HKD","LU2106854487.HKD","LU2089984988.USD","LU2237438978.USD","LU1917777945.USD","LU1974910355.USD"],"gpt_icon":0},{"id":"2611163541","title":"HSBC Adjusts Price Target on Regeneron Pharmaceuticals to $990 From $985, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2611163541","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611163541?lang=en_us&edition=fundamental","pubTime":"2026-02-13 22:32","pubTimestamp":1770993171,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals (REGN) has an average rating of overweight and mean price target of $875.67, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic resea","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["REGN","HSBC"],"gpt_icon":0},{"id":"2611150807","title":"Sanofi Stock Near 52-Week Low As Leadership Shakeup Rattles Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2611150807","media":"Benzinga","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611150807?lang=en_us&edition=fundamental","pubTime":"2026-02-13 21:23","pubTimestamp":1770988980,"startTime":"0","endTime":"0","summary":"Sanofi shares drop after CEO exit and pipeline concerns grow, even as Dupixent sales jump in latest quarter.","market":"nz","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/02/13/Sanofi-SA.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/02/13/Sanofi-SA.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/health-care/26/02/50607808/sanofi-stock-near-52-week-low-as-leadership-shakeup-rattles-investors","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/26/02/50607808/sanofi-stock-near-52-week-low-as-leadership-shakeup-rattles-investors","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["LU2023250504.SGD","LU2362541513.USD","LU2089984988.USD","SNYNF","LU0823434740.USD","BK4585","LU0882574055.USD","LU0823434583.USD","LU0289739699.SGD","LU1917777945.USD","BK4007","IE00BFXG1179.USD","LU0114720955.EUR","BK4211","BK4588","SNY","BK4217","ISBC","LU0823416689.USD","LU0109394709.USD","LU2106854487.HKD","SMA","LU0320765992.SGD","LU0889565916.HKD","LU0058720904.USD","LU2362540622.SGD","LU0053666078.USD","REGN","BK4139","LU1974910355.USD","LU2468319806.SGD","LU2362541273.HKD","LU2237438978.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.regeneron.com","stockEarnings":[{"period":"1week","weight":-0.0201},{"period":"1month","weight":0.0444},{"period":"3month","weight":-0.0004},{"period":"6month","weight":0.3409},{"period":"1year","weight":0.1238},{"period":"ytd","weight":0.0197}],"compareEarnings":[{"period":"1week","weight":0.0009},{"period":"1month","weight":-0.0099},{"period":"3month","weight":0.0109},{"period":"6month","weight":0.0553},{"period":"1year","weight":0.1374},{"period":"ytd","weight":0.0007}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.514286,"avgChangeRate":0.03675},{"month":2,"riseRate":0.428571,"avgChangeRate":0.087062},{"month":3,"riseRate":0.470588,"avgChangeRate":-0.044318},{"month":4,"riseRate":0.470588,"avgChangeRate":0.017191},{"month":5,"riseRate":0.628571,"avgChangeRate":0.057479},{"month":6,"riseRate":0.428571,"avgChangeRate":0.006745},{"month":7,"riseRate":0.657143,"avgChangeRate":0.052646},{"month":8,"riseRate":0.542857,"avgChangeRate":0.022877},{"month":9,"riseRate":0.457143,"avgChangeRate":0.023281},{"month":10,"riseRate":0.4,"avgChangeRate":-0.00141},{"month":11,"riseRate":0.542857,"avgChangeRate":0.046018},{"month":12,"riseRate":0.485714,"avgChangeRate":0.043803}],"exchange":"NASDAQ","name":"Regeneron Pharmaceuticals","nameEN":"Regeneron Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Regeneron Pharmaceuticals(REGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Regeneron Pharmaceuticals(REGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Regeneron Pharmaceuticals,REGN,Regeneron Pharmaceuticals股票,Regeneron Pharmaceuticals股票老虎,Regeneron Pharmaceuticals股票老虎国际,Regeneron Pharmaceuticals行情,Regeneron Pharmaceuticals股票行情,Regeneron Pharmaceuticals股价,Regeneron Pharmaceuticals股市,Regeneron Pharmaceuticals股票价格,Regeneron Pharmaceuticals股票交易,Regeneron Pharmaceuticals股票购买,Regeneron Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Regeneron Pharmaceuticals(REGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Regeneron Pharmaceuticals(REGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}